Paxman AB (publ) (PAX.ST)
SEK 75.6
(-1.05%)
SEK 75.6
(-1.05%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 12.61 Million SEK | 1137.66% |
| 2022 | -1.21 Million SEK | 88.5% |
| 2021 | -10.57 Million SEK | 9.55% |
| 2020 | -11.69 Million SEK | -804.1% |
| 2019 | -1.29 Million SEK | 72.96% |
| 2018 | -4.78 Million SEK | 29.64% |
| 2017 | -6.79 Million SEK | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | 10.6 Million SEK | 43.16% |
| 2024 Q1 | 7.4 Million SEK | 62.25% |
| 2023 Q3 | 8.13 Million SEK | 413.0% |
| 2023 FY | 12.61 Million SEK | 1137.66% |
| 2023 Q1 | -1.66 Million SEK | -119.01% |
| 2023 Q2 | 1.58 Million SEK | 195.42% |
| 2023 Q4 | 4.56 Million SEK | -43.87% |
| 2022 Q1 | -6.89 Million SEK | -162.93% |
| 2022 Q4 | 8.73 Million SEK | 997.86% |
| 2022 Q3 | 796 Thousand SEK | 120.49% |
| 2022 Q2 | -3.88 Million SEK | 43.64% |
| 2022 FY | -1.21 Million SEK | 88.5% |
| 2021 Q1 | -2.35 Million SEK | 64.2% |
| 2021 Q2 | -3.81 Million SEK | -62.51% |
| 2021 Q3 | -4.79 Million SEK | -25.56% |
| 2021 Q4 | 10.95 Million SEK | 328.43% |
| 2021 FY | -10.57 Million SEK | 9.55% |
| 2020 Q1 | 3.06 Million SEK | 213.33% |
| 2020 Q3 | -2.22 Million SEK | -30.96% |
| 2020 Q4 | -6.56 Million SEK | -194.48% |
| 2020 FY | -11.69 Million SEK | -804.1% |
| 2020 Q2 | -1.7 Million SEK | -155.6% |
| 2019 Q4 | -2.7 Million SEK | -310.03% |
| 2019 FY | -1.29 Million SEK | 72.96% |
| 2019 Q1 | -230 Thousand SEK | 89.38% |
| 2019 Q2 | 606 Thousand SEK | 363.48% |
| 2019 Q3 | 1.28 Million SEK | 112.21% |
| 2018 Q3 | -215 Thousand SEK | 72.29% |
| 2018 Q4 | -2.16 Million SEK | -907.44% |
| 2018 Q2 | -776 Thousand SEK | 52.25% |
| 2018 FY | -4.78 Million SEK | 29.64% |
| 2018 Q1 | -1.62 Million SEK | 68.52% |
| 2017 FY | -6.79 Million SEK | 0.0% |
| 2017 Q1 | -333 Thousand SEK | 0.0% |
| 2017 Q2 | 875 Thousand SEK | 362.76% |
| 2017 Q3 | -2.45 Million SEK | -381.03% |
| 2017 Q4 | -5.16 Million SEK | -109.92% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Acarix AB (publ) | -77.55 Million SEK | 116.271% |
| ADDvise Group AB (publ) | 300.6 Million SEK | 95.802% |
| ADDvise Group AB (publ) | 300.6 Million SEK | 95.802% |
| Arcoma AB | 4.66 Million SEK | -170.794% |
| Bactiguard Holding AB (publ) | -131.93 Million SEK | 109.565% |
| BICO Group AB (publ) | -618.3 Million SEK | 102.041% |
| Boule Diagnostics AB (publ) | 39.27 Million SEK | 67.866% |
| CellaVision AB (publ) | 167.05 Million SEK | 92.446% |
| Clinical Laserthermia Systems AB (publ) | -65.93 Million SEK | 119.139% |
| Chordate Medical Holding AB (publ) | -29.57 Million SEK | 142.673% |
| C-Rad AB (publ) | 44.24 Million SEK | 71.479% |
| Duearity AB (publ) | -25.76 Million SEK | 148.981% |
| Dignitana AB (publ) | -15.02 Million SEK | 183.981% |
| Episurf Medical AB (publ) | -94.8 Million SEK | 113.311% |
| Getinge AB (publ) | 3.81 Billion SEK | 99.669% |
| Scandinavian Real Heart AB (Publ) | -68.44 Million SEK | 118.436% |
| Iconovo AB (publ) | -45.77 Million SEK | 127.566% |
| Integrum AB (publ) | 6.51 Million SEK | -93.771% |
| Luxbright AB (publ) | -25.8 Million SEK | 148.902% |
| Mentice AB (publ) | -679 Thousand SEK | 1958.468% |
| OssDsign AB (publ) | -91.95 Million SEK | 113.723% |
| Promimic AB (publ) | -9.11 Million SEK | 238.397% |
| Qlife Holding AB (publ) | -168.69 Million SEK | 107.48% |
| SciBase Holding AB (publ) | -53.93 Million SEK | 123.395% |
| ScandiDos AB (publ) | -13.48 Million SEK | 193.592% |
| Sectra AB (publ) | 518.49 Million SEK | 97.566% |
| Sedana Medical AB (publ) | -65.54 Million SEK | 119.252% |
| Senzime AB (publ) | -133.74 Million SEK | 109.435% |
| SpectraCure AB (publ) | -21.35 Million SEK | 159.103% |
| Stille AB | 44.95 Million SEK | 71.928% |
| Vitrolife AB (publ) | -3.58 Billion SEK | 100.352% |
| Xvivo Perfusion AB (publ) | 38.5 Million SEK | 67.228% |